Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
Lifirafenib
Potential treatment - theoretical effect Experimental Antiviral Aug/11/2020
Radotinib
Potential treatment - theoretical effect Experimental Antiviral Aug/11/2020
Ramipril benzyl ester
Potential treatment - theoretical effect Experimental Antiviral Oct/06/2020
Cyclosporin B
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
7-bromo-5-chloro-8-hydroxyquinoline
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/11/2021
FC05
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
P10
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
P8
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
W25
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/08/2021
Lividomycin
Potential treatment - theoretical effect Experimental Antiviral Jul/23/2020
5-Imidazol-1-ylmethyl-quinolin-8-ol
Potential treatment - theoretical effect Experimental Antiviral Jan/27/2021
[2-[[(3R)-1,1-Dioxothiolan-3-yl]-(2-methylpropyl)amino]-2-oxoethyl] 3-(furan-2-carbonylamino)-4-methylbenzoate
Potential treatment - theoretical effect Experimental Antiviral Sep/17/2020
AR-12
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/20/2020
[2-[[(2R)-Butan-2-yl]-[(3R)-1,1-dioxothiolan-3-yl]amino]-2-oxoethyl] 3-(furan-2-carbonylamino)-4-methylbenzoate
Potential treatment - theoretical effect Experimental Antiviral Sep/17/2020
P17
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
H014
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
Capsazepine
Potential treatment - theoretical effect Experimental Antiviral Sep/18/2020
P5A-3C12
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/17/2021
ABBV-744
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020
AC-55541
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020